combination therapy with glp-1 receptor agonist and sglt2 inhibitor Effect of treatment glucagon-like peptide-1 agonists sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study The combination of glucagon-like peptide-1

Diabet Obes Metab 22:12921301

doi: 10.1161/CIRCULATIONAHA.112.091215

Common side effects of semaglutide are usually mild and may include: Nausea Vomiting Diarrhea Constipation Abdominal pain Decreased appetite Indigestion The majority of side effects are transient and typically resolve spontaneously

High fat diet and GLP-1 drugs induce pancreatic injury in mice

25 Although data from clinical studies on liraglutide revealed a 7% increase in serum amylase and a 31% increase in serum lipase in patients after four weeks of GLP-1 receptor agonist treatment compared with placebo, the increased levels reverted to normal once therapy was discontinued and did not predict acute pancreatitis onset

Leah Joseph, MD, FACP , youll receive a personalized treatment plan designed to support long-term weight management and metabolic health